GLI2 Is a Potential Therapeutic Target in Pediatric Medulloblastoma

• DOI: 10.1097/nen.0b013e31821b94db
• Publication Date: 2011-05-13T09:20:03Z
• Authors: Pawel Buczkowicz; Jing Ma; Cynthia Hawkins
• Keywords: GLI2

To determine whether the zinc finger transcription factors GLI1 to GLI3 and suppressor of fused (SUFU) components Sonic hedgehog signaling pathway may be prognostic markers potential therapeutic targets in pediatric medulloblastoma (MB), we investigated relationship expression these proteins prognosis MB 124 patients who had undergone surgery atthe Hospital for Sick Children (Toronto, Ontario, Canada). The expressions (p = 0.011) GLI2 0.003), but not 0.774) or SUFU 0.137), were associated with a worse overall survival by Kaplan-Meier analysis. Overall positive was 6.01 ± 0.85 years 5.27 1.44 years, respectively, versus 10.11 1.52 10.18 0.22 negative GLI2, respectively. Knockdown 3 cell lines resulted decreased number viability, as determined MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay; knockdown no effect. decrease causedby G0 cycle arrest; there induction apoptosis. These results suggest that targeting useful adjuvant strategy MB.